Sequoia and Greenoaks co-lead Isomorphic Labs' round to take AI-designed drugs to trials
The London company, founded in 2021, said it raised a $5 billion Series C with Alphabet, Thrive Capital and all other existing investors taking part.
Add FinanceInTime as a preferred source on Google
Isomorphic Labs, a London company founded in 2021 that uses AI to design medicines, announced a $5 billion Series C on November 17, co-led by Greenoaks and Sequoia Capital, according to its press release. It is the company's third disclosed outside round in 596 days (computed).
Three rounds, each bigger than the last
The company's first external round, announced on March 31, 2025, raised $600 million, led by Thrive Capital with participation from GV and follow-on capital from existing investor Alphabet. A $2.1 billion Series B followed on May 12, 2026, led by Thrive Capital, the company said, with new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
The Series C came 189 days after the Series B (computed). The three announced rounds add up to $7.7 billion (computed). The company did not disclose a valuation for the Series C, and the release does not say how much of the round Alphabet or any other investor supplied.
Who is in the round
Andreessen Horowitz and several other new investors joined, with "continued significant investment from Alphabet," the company said. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company described the round as oversubscribed.
What the drug design engine is, in the company's words
Isomorphic Labs says its drug design engine, called IsoDDE, "unifies a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities." It is combined with what the company calls proprietary agents that reason over biological systems.
The company said the engine is "yielding positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry." The release names no drug candidate, partner or trial date. The company is headquartered in London and has offices in Cambridge, Massachusetts and Lausanne, Switzerland.
What the founder and the investors say
Sir Demis Hassabis, Founder and CEO, said: "When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI." Of the engine he said it "is generating molecules with unprecedented precision and speed."
Max Jaderberg, the company's President, said: "Every week we are making repeatable scientific advancements enabled by our models." Neil Mehta, Founder and Managing Partner of Greenoaks, said the firm believes the team is "building the future of AI-led drug discovery." Konstantine Buhler, a Partner at Sequoia Capital, said it is "inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates."
Where the company says the money goes
The company said it will keep maturing IsoDDE, expand "deeper into new biology with highly advanced models," build a partner ecosystem, and support "scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials." Hassabis said the round lets the company drive "our first therapeutic programs towards clinical trials."
Capital is ahead of evidence, and the next milestone is a trial
Our view is that this round is a milestone, not proof. We think the sources show a company that investors have funded three times in under two years, and show nothing yet about what a patient or a customer pays for: no revenue, no named trial, no valuation. The opportunity is that a drug design engine with repeatable results could shorten the path to the clinic; the threat is that capital arrives faster than clinical evidence, which a trial can contradict.
We expect the next test to be the company's first announcement of a program entering clinical trials, and we would change this view if the company names a candidate and a date or, on the other side, if it discloses delays. Funding says investors believe in the model, and a trial would say whether the medicine works.
The view in this final section is FinanceInTime's editorial opinion, for information only. It is not investment, tax, legal or other advice, and it does not take your circumstances into account. Forecasts are uncertain and past results do not guarantee future ones.
Sources
- Isomorphic Labs announces $5 Billion Series C funding (press release) — Isomorphic LabsPrimary source
- Isomorphic Labs announces Series C investment round — Isomorphic LabsPrimary source
- Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine (press release) — Isomorphic LabsPrimary source
- Isomorphic Labs announces $600m external investment round — Isomorphic LabsPrimary source
More in Startup Radar
View All Startup Radar
Startup Radar · Analysis
Mercor's $20 billion Series D funds a move from AI labs to enterprise customers


